Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06646913 · ClinicalTrials.gov registry record · Phase 1
TENS in Scleroderma
A Phase 1 study of Gastroparesis and Scleroderma, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT06646913 is a Phase 1 study of Gastroparesis and Scleroderma that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 16 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06646913, a Phase 1 study of Gastroparesis and Scleroderma, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma. Participants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.
Conditions Studied
Interventions
- DEVICE Transcutaneous Electrical Nerve Stimulation
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06646913
The ClinicalTrials.gov registry entry for NCT06646913 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (95% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Transcutaneous Electrical Nerve Stimulation is the first listed.
NCT06646913 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT06646913 about?
NCT06646913 is a clinical study titled "TENS in Scleroderma". The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating ...
What is the current status of trial NCT06646913?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2024-10-01. Estimated completion is 2026-05.
What conditions does trial NCT06646913 study?
This clinical trial studies the following conditions: Gastroparesis, Scleroderma, Systemic Sclerosis (SSc).
What interventions are being tested in trial NCT06646913?
The interventions under investigation include: Transcutaneous Electrical Nerve Stimulation (DEVICE).
Who is sponsoring clinical trial NCT06646913?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06646913 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
COMPLETED · Phase 1
-
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
COMPLETED · Phase 1
-
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
COMPLETED · Phase 1
-
Gastroparesis Registry 4
RECRUITING
-
The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM
RECRUITING · NA
-
Study of Gastric Motility in Eosinophilic Gastritis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.